30 May 2012, BioSpectrum Bureau , BioSpectrum
Singapore: The Board of Directors of Sun Pharmaceutical Industries appointed Mr Israel Makov as chairman of the Board. Mr Makov is the former president and CEO of Teva Pharmaceutical Industries. He is among Israel's most respected corporate leaders, and is widely credited with Teva's emergence as a global company and a world leader in generic pharmaceuticals.
Headquartered in India, Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
Speaking on the induction, Mr Dilip Shanghvi, managing director of Sun Pharma, said, "I welcome Mr Makov on behalf of the entire Board and the larger Sun Pharma team. He is an exceptional leader with deep knowledge and experience in globalizing businesses successfully. As Sun Pharma continues to rapidly expand its presence worldwide, I am sure that we will benefit immensely from his experience."
"I am happy to accept the position of chairman of the Board. Sun Pharma is an exciting company poised for substantial global expansion and I look forward to working together with Dilip and his team in realizing their visionary goals," said Mr Makov.
Mr Makov joined Teva in 1995 and led the company's global expansion, managing over 12 acquisitions - two of which were the largest M&A deals in the Israeli history at the time. Under Mr Makov's leadership, Teva became the undisputed global leader in generic pharmaceutical industry and a global leader in the treatment of multiple sclerosis. Prior to joining Teva in 1995, Mr Makov led a number of companies in various industries, and founded Israel's first biotech company, Interpharm, which went public in the US as the first Israeli company in R&D stage.